Introduction
Tumor-specific cytotoxic T lymphocytes (CTLs) are believed to play a major role in the control of tumor growth, which resulted in the strategy to generate ex vivo T cells with defined antigen specificity for the use in adoptive immunotherapy of cancer. 1, 2 However, the peripheral T-cell repertoire is usually devoid of high-avidity tumor-specific CTLs due to thymic selection. 3 Tumor-specific CTLs are moreover often anergic or exhibit a limited life span. [3] [4] [5] Transgenic expression of a T-cell receptor (TCR) aims to circumvent these constraints. Ex vivo T cells from the peripheral blood of healthy donors, as well as of cancer patients, can be retrovirally transduced to express a TCR to reprogram the T cell with a new specificity. [6] [7] [8] [9] [10] Although T cells engineered with a transgenic TCR have been successfully applied in cancer therapy, 11 the strategy is hampered by the fact that it requires HLA-restricted antigen presentation by the tumor, whereas many malignant cells display defects in antigen processing and HLA expression, which render them invisible to CTL responses. 2, [12] [13] [14] Artificially engineered chimeric antigen receptors or immunoreceptors circumvent these limitations by employing an antibody-derived binding domain that recognizes a tumor surface antigen in its natural unprocessed form, and is directly linked to the intracellular TCRz chain to provide T-cell stimulation. 15 The redirected specificity of these cells is defined by the antibody-binding domain, and the modular composition of the immunoreceptor allows cointegration of additional signaling domains, including the intracellular CD28 costimulatory domain. 16 The feasibility of the strategy has been shown in vitro, 17, 18 as well as in animal models. 19 Clinical studies using immunoreceptors have been initiated. 20 The receptor-transfer strategies described above, all used retroviral or lentiviral transduction of effector T cells, which results in stable genomic integration of the transgene. This allows for constitutive expression of the transgenic TCR for at least several months. However, the integration of the provirus into the genome bears the risk of insertional mutagenesis and, at least theoretically, malignant transformation of the T cells, although neoplastic transformation of differentiated T cells as result of a retroviral gene transfer has not been observed so far, and therefore does not represent a major concern of the strategy. Nevertheless, stable expression of the transgene may be a disadvantage when unintended cross-reactivity of the transgenic immunoreceptor results in severe autoaggression. This was recently observed in a clinical trial with renal cell carcinoma patients. 21 The targeted antigen, carbonic anhydrase IX, turned out to be expressed not only on renal carcinoma cells but also on bile duct endothelium, which resulted in grade 2-4 liver toxicity. Although the study showed the impressive effectiveness of redirected T cells in vivo, there is an obvious need to limit the ongoing immune reaction when severe autoimmunity occurs.
Several approaches were developed to specifically eliminate engineered T cells. [22] [23] [24] However, the risk that a few remaining cells may sustain autoaggression is present in all these strategies.
A new innovative approach that avoids these risks of retroviral transduction is the electroporation of mRNA into T cells. 9, 11, 25, 26 Owing to the limited half-life and the lack of stable genomic integration, RNA-based immunoreceptor expression is transient. If an autoreactive T cell is unintendedly generated, the autoaggressive pathology will be limited due to the short half-life of the immunoreceptor expression, without the need of therapeutic T-cell elimination.
Here we compared the immunoreceptor-triggered activation of T cells engineered to express immunoreceptors after RNA or retroviral gene transfer. Two immunoreceptors were used in this study, anti-ErbB2 27, 28 and anti-CEA, 16, 29 both targeting tumor-associated antigens expressed on a broad variety of cancer types. Here we show in a comparative setting that human T cells from peripheral blood can be engineered by RNA transfer as efficiently as by retroviral gene transfer to express the immunoreceptor. T cells reprogramed by RNA transfer are fully functional and are activated by the immunoreceptor, resulting in immunoreceptor-triggered cytokine production and specific tumor cell lysis. Moreover, immunoreceptor expression upon RNA transfer is transient, providing a strategy to generate large numbers of tumor-specific, safe, and self-limiting T lymphocytes for the immunotherapy of cancer.
Results

RNA transfer allows for the transient expression of immunoreceptors in T cells
To explore the RNA transfer technology as a tool to redirect the specificity of T cells, we used two different immunoreceptors, the scFv-anti-erbB2-CD28-z immunoreceptor specific for ErbB2 (Her2/neu) and the BW431/ 26scFv-Fc-CD28-CD3z immunoreceptor specific for CEA. Both CD4 + and CD8 + T cells were engineered by RNA electroporation, as the chimeric immunoreceptors are independent of CD4 or CD8 coreceptor binding. At least half of the T cells survived the electroporation procedure (data not shown). We determined the expression of immunoreceptors by flow cytometry, making use of an myc-tag, which is integrated in the extracellular part of the ErbB2-specific receptor, and the IgG1 Fc domain, which is contained in the CEA-specific receptor. T cells transfected without RNA served as negative control. As early as 4 h after electroporation, 83.0±6.4% (average of three independent experiments ± s. (Figure 1a lower panels). The levels of immunoreceptor expression, as determined by mean fluorescence intensity, were similar in CD4 + and CD8 + T cells (Figure 1b) . For the ErbB2-specific immunoreceptor, the highest expression was measured at 4 (CD4 + T cells) or 24 h (CD8 + T cells) after electroporation (Figure 1b left panel) . For the CEA-specific immunoreceptor (Figure 1b right panel) , the highest expression was measured after 4 or 24 h. Receptor expression then gradually decreased with time and was not detectable anymore at day 9 after electroporation ( Figure 1b) . These data show that chimeric T-cell receptors can indeed be introduced with high efficiency into bulk CD4 + and CD8 + T cells by RNA electroporation and that the immunoreceptor cell surface expression is transient. The main duty of cytotoxic CD8 + T cells is to kill target cells after antigen recognition. Therefore, we investigated whether the same target cells, which mediated T-cell activation are lysed by redirected T cells engineered by RNA electroporation in a short-term, that is, 4-6 h, chromium-release assay. CD8 + T cells transfected with the ErbB2-specific immunoreceptor lysed ErbB2 + SK-OV-3 tumor cells in a dose-dependent manner (Figure 3a ). Cytolysis by reprogramed T cells was antigen specific because the lysis of ErbB2 + tumor cells was completely blocked by adding soluble recombinant ErbB2 ( Figure  3a ). In line with these results, RNA-transfected CD8 + T cells expressing the CEA-specific immunoreceptor exhibited specific cytolytic activity against CEA + KATO III, but not against CEA À SK-OV-3 tumor cells ( Figure 3b ). T cells electroporated without RNA did not lyse any of the tumor cells (Figures 3a and b) . Taken together, RNAengineered CD8 + T cells exhibit potent, immunoreceptormediated antigen-specific cytolysis toward tumor cells.
Comparison of RNA-transfected and retrovirally transduced T cells
Although we showed that T cells can be reprogramed with a tumor specificity by RNA electroporation, the question remained whether these T cells are as efficient as retrovirally transduced T cells in mediating specific effector functions. Therefore, we compared the RNA transfection with the standard retroviral transduction procedure using CD8 + T cells from the same donor and the CEA-specific immunoreceptor BW431/26scFv-Fc-CD28-CD3z. As shown in Figure 4 , retrovirally transduced T cells produced IFNg in a dose-dependent fashion in response to CEA + LS174T tumor cells, but not after coincubation with CEA À COLO-320 tumor cells (Figure 4b ). RNA-electroporated T cells also produced IFNg after stimulation with the same tumor + and CD8 + T cells was determined by FACS analysis 4 h after electroporation by staining the immunoreceptors using the anti-myc-tag antibody for the ErbB2-specific immunoreceptor (black histograms; upper panels) and the anti-Fc antibody for the CEA-specific immunoreceptor (black histograms; lower panels). T cells electroporated without RNA served as control (gray histograms). All data are representative for three standardized independent experiments. (b) The expression levels of the ErbB2-specific (left panel) and CEA-specific (right panel) immunoreceptors on CD4 + and CD8 + T cells were determined by flow cytometry at several time points (as indicated), and depicted as specific mean fluorescence intensity (specific MFI) after subtraction of the background MFI of cells electroporated without RNA. Shown are means of X three independent experiments ± s.e.m. FACS, fluorescence-activated cell sorter. À SK-OV-3, ErbB2 -MDAMB468, and CEA + KATO III. T cells with the anti-ErbB2 immunoreceptor were additionally incubated in the presence of recombinant, soluble ErbB2 protein (1 mg ml À1 ) to block the ErbB2-specific receptor (a; gray bars). T cells electroporated without RNA served as controls (white bars). Cytokine production was determined by a cytometric bead array as described in Materials and methods. The data shown are representative for one out of three experiments. nd, not determined; rec., receptor. 
Discussion
In this study we show that CD4 + and CD8 + T cells can be manipulated by RNA transfer to express two different recombinant immunoreceptors specific for ErbB2 and CEA. The immunoreceptors consist of the antigenbinding domain derived from an antibody fused to the CD3z signaling and CD28 costimulatory domains. RNA encoding the immunoreceptors was transferred to T cells by electroporation, which is a vector-independent transfer system. RNA electroporation initially was used to modify dendritic cells to express tumor antigens 30, 31 or to functionally manipulate these cells. 32, 33 Subsequently, RNA electroporation was used to transfer full-length TCR to T cells to redirect them with a new specificity. 9, 11, 25, 26 Owing to the fact that RNA does not integrate into the genome and is quickly degraded, this technique has certain advantages over retroviral transduction.
Here we show that mRNA electroporation is an efficient tool to functionally express recombinant immunoreceptors in T cells, redirecting them to their cognate target cells. T-cell activation by ErbB2 binding of the immunoreceptors was specific as T-cell activation was blocked by addition of an excess of soluble recombinant ErbB2 protein (1 mg ml À1 ), and T cells, transfected with an immunoreceptor of irrelevant specificity were not activated in the presence of ErbB2 + target cells (Figures 2 and 3) . In case of the CEA-specific immunoreceptor, the antibody-derived binding domain specifically binds the membrane-associated form of CEA, 34 thereby avoiding receptor blocking by soluble CEA, which is present in high concentrations in sera of many patients with gastrointestinal cancer. 35 Comparisons of the functional capacities of CD8 + T cells either retrovirally transduced or RNA transfected with the same immunoreceptor showed that the RNA-transfected T cells produce IFNg and were cytolytic, although at lower levels (Figures 4 and 5) .
The use of chimeric immunoreceptors has an additional advantage over the use of natural TCRs. Although the latter can only see short protein epitopes, chimeric immunoreceptors have a binding domain that is derived from an antibody. This allows targeting of a far broader range of molecular structures on the tumor cells, which can be more specific for malignant tissue. For example, alternatively glycosylated proteins and other non-protein structures can be aimed at. As many tumors deregulate their post-translational glycosylation patterns, these antigens can provide a better specificity for the tumor than protein antigens alone, as shown for the heavily glycosylated tumor surface marker MUC1. 36 The procedure of RNA transfection is very fast in comparison with retroviral gene transfer and results in high numbers of modified T cells, that is, more than 80% expressed the immunoreceptor after transfection, rendering selection and excessive ex vivo expansion of engineered T cells unnecessary. Since up to 2 Â 10 9 
Transfection of T cells with immunoreceptor RNA
K Birkholz et al CD8 + T cells can be generated from a lymphapheresis, 37 sufficient numbers of T cells can be generated ex vivo. The electroporation of such quantities of T cells is technically feasible (unpublished observations). Under certain circumstances, it may be necessary to briefly expand these cells before electroporation. In contrast, extensive expansion, as often required after retroviral transduction should be avoided as it can result in conversion of T cells into the effector memory phenotype, leading to reduced effector functions and low antitumor activity. 5, 38 Immunoreceptor expression on the T-cell surface was found to be transient with a half-maximal expression after approximately 2 days, and an absence of expression after 9 days (Figure 1 ). Engineered T cells can be activated by specific antigen binding only during this time. Loss of immunoreceptor expression results in the loss of redirected specificity. Retroviral gene transfer allows for clonal expansion of the transduced T cells without significant loss of the transgenic immunoreceptor during the first weeks. 17 In contrast, transient immunoreceptor expression does not allow in vivo expansion of transfected T cells after adoptive transfer, which is frequently considered as a disadvantage compared with retroviral transduction. In case of unintended autoimmune reactions, however, transient immunoreceptor expression in vivo may be an advantage. The danger of autoreactive, redirected T cells became obvious in a recent trial with patients suffering from metastatic renal cell carcinoma. T cells retrovirally reprogramed with an immunoreceptor specific for carbonic anhydrase IX destroyed antigen-expressing cells of the bile ducts, leading to severe liver toxicity. 21 Although redirected T cells were successfully eliminated in these patients by immunosuppressive treatment, T cells engineered by RNA transfer would exhibit selflimiting autoaggression by cessation of immunoreceptor expression after approximately 9 days. Owing to transient intracellular persistence of transferred RNA, T cells engineered by RNA transfection have an intrinsic 'receptor off switch', which will result in loss of the immunoreceptor, and thereby limit the redirected immune response. As a consequence, on the other hand, immunotherapy using these cells will require repetitive applications, and no long-lasting memory will be established.
Although the transient expression of the introduced receptors can be an advantage with respect to safety, it is questionable whether the grafted T cells can find their target cells in time, if they are applied intravenously. To support this, we show that RNA-electroporated T cells maintain their lytic capacity after 2 days of activation matching the cytotoxic activity of retrovirally transduced T cells ( Figure 5) .
To reduce the time needed by the T cells to encounter targets, and to decrease the required number of transfected cells, we suggest to inject these cells directly into the tumor, if accessible. This would overcome different requirements in adoptive T cell therapy such as extravasation or local expansion of the introduced T cells. By breaking the immunosuppressive milieu in the tumor, epitope spreading could be induced which correlates with positive clinical outcome. 39 By RNA transfer, the mRNA of interest can be delivered as a minimal expression RNA without any additional vector elements, which makes integration into the host genome impossible. This is in contrast to retroviral transduction of a transgene, which results in provirus integration randomly into the genome of the host cell. Thus, retroviral integrations may occur in or near genes involved in cell-cycle control. This situation became obvious in a clinical trial of severe combined immunodeficiency (SCID) where autologous hematopoietic stem cells were retrovirally transduced. Some treated individuals developed leukaemia-like symptoms due to the integration of the provirus into the LMO-2 oncogene. 40, 41 The risk of malignant transformation of differentiated T lymphocytes upon retroviral gene transfer, however, is substantially lower, 3,22,42 but can certainly not be excluded on the individual basis.
Regulatory hurdles to apply RNA transfection in clinical trials are much lower compared to those of retroviral transduction, as RNA transfection does obviously not represent transfer of gene(s) and does not result in permanent genetic alterations of the target cell. RNA and retroviral transfer procedures to generate redirected T cells may be combined in a two-step clinical trial protocol. The initial clinical testing of new immunoreceptors may be carried out by RNA-electroporated T cells checking for effectivity. Prominent autoimmunity 
Materials and methods
Cells
T cells were prepared from peripheral blood of healthy volunteers obtained following informed consent and approved by the institutional review board. Peripheral blood mononuclear cells were isolated by density centrifugation using Lymphoprep (Axis-Shield, Oslo, Norway). CD4 + and CD8 + T cells were isolated by magnetic activated cell sorting (Miltenyi, Bergisch Gladbach, Germany) according to the manufacturer's instructions. T cells were cultured in MLPC medium consisting of RPMI 1640, 10% (v/v) human serum, 2 mM L-glutamine, 20 mg l À1 gentamicin, 10 mM HEPES (PAA Labortechnik, Pasching, Austria), 1 mM sodium pyruvate (Sigma-Aldrich), 1% (v/v) MEM nonessential amino acids (100 Â , PAA Labortechnik), supplemented with 20 U ml À1 IL-7 (ProSpec, Rehovot, Israel), or in R10 medium consisting of RPMI 1640 supplemented with 2 mM L-glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin (BioWhittaker), 10% (v/v) fetal calf serum (PAA Labortechnik), 2 mM HEPES and 2 mM 2-mercaptoethanol (Invitrogen, Karlsruhe, Germany). The T cells were used for RNA electroporation or retroviral gene transfer 16-20 h after MACS separation. The following target cell lines, either expressing the ErbB2 (Her2/ neu) 43, 44 or the carcinoembryonic antigen (CEA) 45 were used: the CEA + gastric cancer line KATO III (kindly provided by Saskia Santegoets and Tanja de Gruijl), the CEA + colorectal adenocarcinoma line LS174T, the ErbB2 + ovarian adenocarcinoma line SK-OV-3, the CEA À cell line COLO-320, and the ErbB2 À breast adenocarcinoma line MDAMB 468 (all from ATCC). 46 The cell lines LS174T, COLO-320, and SK-OV-3 were cultured in R10 medium. The cell lines KATO III and MDAMB 468 were cultured in D-MEM with 4.5 g l À1 D-Glucose and pyruvate (Invitrogen) supplemented with 10% (v/v) fetal calf serum.
Immunoreceptors
The generation of the anti-CEA immunoreceptor BW431/26-scFv-Fc-CD28/CD3z and the anti-ErbB2 immunoreceptor scFv-anti-erbB2-CD28-z were previously described in detail. 16, 27 Retroviral transduction of T cells with immunoreceptors was described in detail elsewhere.
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In vitro transcription of immunoreceptor RNA
The expression cassettes for the ErbB2-specific and the CEA-specific immunoreceptors were recloned from the respective retroviral vectors into the pGEM4Z-5 0 UTR-sig-MAGE-A3-DC.LAMP-3 0 UTR vector (kindly provided by Kris Thielemans), thereby replacing the MAGE-A3-DCLAMP DNA. For in vitro transcriptions, the pGEM4Z-ErbB2-cTCR and pGEM4Z-CEA-cTCR vectors were linearized, purified by phenol/chloroform extraction and ethanol precipitation, and used as DNA templates. The in vitro transcription was performed with T7 RNA polymerase using the mMESSAGE mMA-CHINE T7 Ultra kit (Applied Biosystems/Ambion, TX, USA) according to the manufacturer's instructions. After DNaseI (Applied Biosystems/Ambion) digestion, the transcribed RNA was recovered on RNeasy columns (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The RNA integrity was monitored by standard gel electrophoresis.
RNA electroporation of CD4
+ and CD8 + T cells RNA electroporation of T cells was performed as described previously. 25 Briefly, T cells were washed once with pure RPMI 1640 and once with OptiMEM without phenol red (Lonza, Vervier, Belgium; all at room temperature), and resuspended in OptiMEM at a concentration of up to 14 Â 10 7 cells per ml. RNA was transferred to a 4-mm cuvette (Peqlab, Erlangen, Germany; 150 mg ml À1 final concentration), 100-600 ml of cell suspension was added and pulsed in a Genepulser Xcell (Bio-Rad, Munich, Germany). Pulse conditions were square-wave pulse, 500 V, 5 ms. Immediately after electroporation, the cells were transferred to MLPC medium supplemented with 20 U ml À1 IL-7, or for determination of the expression kinetics of the CEAspecific immunoreceptor in R10 medium supplemented with 20 U ml À1 IL-7.
Flow cytometric analyses
ErbB2 and CEA expression on the tumor cells was determined by flow cytometry using the anti-CEA-FITC antibody (abcam, Cambridge, UK) for CEA expression and anti-Her2/neu-PE (phycoerythrin) antibody (BD Biosciences, Heidelberg, Germany) for ErbB2 expression. BW431/26-scFv-Fc-CD28/CD3z immunoreceptor expression was monitored by flow cytometry using the PE-conjugated F(ab') 2 antihuman IgG1 antibody (0.1 mg ml
À1
; Southern Biotech, Birmingham, AL, USA) directed against the extracellular IgG1 CH2CH3 domain of the immunoreceptor. The scFv-anti-erbB2-CD28-z immunoreceptor expression was monitored using the anti-myc-tag-Alexa Flour 588 antibody (Cell signaling, Boston, MA, USA) directed against the extracellular myctag of the immunoreceptor. Immunofluorescence was analyzed using a FACScan cytofluorometer equipped with CellQuest software (BD Biosciences). During longterm monitoring of receptor expression, MLPC medium (ErbB2-specific immunoreceptor) or R10 medium (CEAspecific immunoreceptor) was refreshed every second day and 10 ng ml À1 IL-7 and 5 ng ml À1 IL-15 (R&D, Minneapolis, MN, USA) were added. Cell debris was eliminated from the analysis using a gate on forward and side light scatter. A minimum of 10 4 cells was analyzed for each sample.
T-cell activation
Transfected T cells were harvested 4 h after electroporation and cocultured over night with tumor cells at a ratio of 1:1 (50 000 cells each) in 100 ml MLPC medium. IL-2, IL-4, IL-6, IL-10, TNFa, and IFNg concentrations in the supernatant were determined using a Th1/Th2 cytometric bead array (BD Biosciences) according to the manufacturer's instructions. Alternatively, culture supernatants were analyzed for IFNg by enzyme-linked immunosorbent assay utilizing matched pairs of antibodies specific for IFNg (clones NIB 42 and B133.5) (BD ). The reaction product was visualized by a peroxidase-streptavidin conjugate (1:10 000) and ABTS (both purchased from Roche Diagnostics, Mannheim, Germany) as substrate. The detection limit of the assay is 15 pg ml À1 IFNg.
Specific cytotoxicity
Short-term cytotoxicity was tested in standard 4-6 h 51 Crrelease assays as described previously. 25 Briefly, target cells were labeled with 100 mCi of Na 2
51
CrO 4 /10 6 cells for 1 h at 37 1C, 5% CO 2 , washed, and 1000 cells per well were cocultured with effector T cells in 96-well plates. Effector cells were added at an effector to target cell ratio of 60:1, 20:1, 6:1, and 2:1. Specific cytolysis (%) was calculated from the released radioactivity as follows: ((experimental releaseÀbackground release)/(maximum releaseÀbackground release) Â 100%). To compare longterm cytotoxicity, T cells were activated with anti-CD3 antibody (OKT3, 100 ng ml
À1
) and IL-2 (400 U ml
) for 2 days and were then retrovirally transduced as described before. 16 RNA-transfected T cells were activated 6 h after electroporation with OKT3 (100 ng ml 
